Jane Street
PMCB icon

Jane Street’s PharmaCyte Biotech PMCB Stock Holding History

Jane Street’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.67K Buy
11,530
+139
+1% +$106 ﹤0.01% 11327
2025
Q4 		$8.25K Buy
+11,391
New +$10.3K ﹤0.01% 10867
2023
Q1 		– Sell
-20,705
Closed -$60.7K – 9721
2022
Q4 		$60.7K Buy
+20,705
New +$59.3K ﹤0.01% 8300

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Jane Street's PMCB Position: Q1 2026 in Review

Jane Street increased its PharmaCyte Biotech (PMCB) stake by 1.2% in Q1 2026, buying an estimated $106 and bringing the position to 11,530 shares worth $7.67K. The position accounts for ﹤0.01% of the portfolio, ranked #11327.

Jane Street first reported a position in PMCB in Q4 2022 and has held it in 3 quarters since. The position peaked at $60.7K in Q4 2022. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Jane Street held 11,530 shares of PharmaCyte Biotech worth $7.67K as of Q1 2026.
  • Jane Street bought 139 PharmaCyte Biotech shares in Q1 2026, an estimated $106.
  • PharmaCyte Biotech made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #11327 holding.
  • Jane Street first reported a position in PharmaCyte Biotech in Q4 2022 and has held it in 3 quarters since.
  • Jane Street's PharmaCyte Biotech position peaked at $60.7K in Q4 2022.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.